Show simple item record

dc.contributor.authorMohammadian, M
dc.contributor.authorShamsasenjan, K
dc.contributor.authorNezhad, PL
dc.contributor.authorTalebi, M
dc.contributor.authorJahedi, M
dc.contributor.authorNickhah, H
dc.contributor.authorMinayi, N
dc.contributor.authorMovassaghpour, A
dc.date.accessioned2018-08-26T09:01:21Z
dc.date.available2018-08-26T09:01:21Z
dc.date.issued2013
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54997
dc.description.abstractMSCs are multipotent progenitors which reside in bone marrow. They support hematopoietic stem cells homing, self renewal and differentiation in bone marrow. They can also differentiate into osteoblasts, adipocytes, chondrocytes, myocyates and many other tissues. In vivo, when trauma happens, MSCs operate cell renewal and migrate to the damaged tissues to regenerate that injury. In vitro, MSCs are able to proliferate and differentiate to a variety of cell lineages. This makes them a very hopeful tool for cell-based regenerative therapy for large bone defects, maxillofacial skeletal reconstruction, cardiovascular and spinal cord injury and so many other defects. The most important characteristic that make MSCs an excellent tool for cell replacement is their ability to escape from immune rejection. For therapeutic purposes they usually isolated from human bone marrow or fat and they should proliferate in order to reach an adequate number for implantation. Conventionally DMEM medium supplemented with 10% FBS is used for their expansion, but currently autologous platelet rich products are replaced FBS. Platelet granules contain so many growth factors that can support MSCs proliferation. é 2013 by Tabriz University of Medical Sciences.
dc.language.isoEnglish
dc.relation.ispartofAdvanced Pharmaceutical Bulletin
dc.subject5' nucleotidase
dc.subjectactivated leukocyte cell adhesion molecule
dc.subjectbeta1 integrin
dc.subjectCD9 antigen
dc.subjectcommon acute lymphoblastic leukemia antigen
dc.subjectendoglin
dc.subjectfibronectin
dc.subjectFlt3 ligand
dc.subjectHermes antigen
dc.subjectinterleukin 11
dc.subjectinterleukin 12
dc.subjectinterleukin 14
dc.subjectinterleukin 15
dc.subjectinterleukin 6
dc.subjectinterleukin 7
dc.subjectinterleukin 8
dc.subjectlaminin
dc.subjectmicrosomal aminopeptidase
dc.subjectplatelet derived growth factor beta receptor
dc.subjectThy 1 antigen
dc.subjectvascular cell adhesion molecule 1
dc.subjectvimentin
dc.subjectantigen presentation
dc.subjectarticle
dc.subjectautologous hematopoietic stem cell transplantation
dc.subjectcardiovascular disease
dc.subjectcell differentiation
dc.subjectcell expansion
dc.subjectcell homing
dc.subjectcell regeneration
dc.subjectcell renewal
dc.subjectclinical effectiveness
dc.subjectcytokine release
dc.subjectdiabetes mellitus
dc.subjectG1 phase cell cycle checkpoint
dc.subjecthuman
dc.subjectimmunomodulation
dc.subjectimmunopathology
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectlung disease
dc.subjectlymphopoiesis
dc.subjectmesenchymal stem cell
dc.subjectmesenchymal stem cell transplantation
dc.subjectmyelopoiesis
dc.subjectneurologic disease
dc.subjectnonhuman
dc.subjectprotein expression
dc.subjectspinal cord injury
dc.subjectstem cell mobilization
dc.subjectstem cell niche
dc.titleMesenchymal stem cells: New aspect in cell-based regenerative therapy
dc.typeArticle
dc.citation.volume3
dc.citation.issue2
dc.citation.spage433
dc.citation.epage437
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.5681/apb.2013.070


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record